|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Late biliary complications in human alveolar echinococcosis are associated with high mortality显示文摘AIM:To evaluate the incidence of late biliary complications in non-resectable alveolar echinococcosis(AE)under long-term chemotherapy with benzimidazoles.METHODS:Retrospective analysis of AE patients with biliary complications occurring more than three years after the diagnosis of AE.We compared characteristics of patients with and without biliary complications,analyzed potential risk factor for biliary complications and performed survival analyses.RESULTS:Ninety four of 148 patients with AE in Zurich had non-resectable AE requiring long-term benzimidazole chemotherapy,of which 26(28%)patients developed late biliary complications.These patients had a median age of 55.5(35.5-65)years at diagnosis of AE and developed biliary complications after 15(8.25-19)years of chemotherapy.The most common biliary complications during long-term chemotherapy were late-onset cholangitis(n=14),sclerosing cholangitis-like lesions(n=8),hepatolithiasis(n=5),affection of the common bile duct(n=7)and secondary biliary cirrhosis(n=7).Thirteen of the 26 patients had undergone surgery(including 12 resections)before chemotherapy.Previous surgery was a risk factor for late biliary complications in linear regression analysis(P=0.012).CONCLUSION:Late biliary complications can be observed in nearly one third of patients with non-resectable AE,with previous surgery being a potential risk factor.After the occurrence of late biliary complications,the median survival is only 3 years,suggesting that late biliary complications indicate a poor prognostic outcome. | Pascal Frei Benjamin Misselwitz Meher K Prakash Alain M Schoepfer Bettina M Prinz Vavricka Beat Müllhaupt Michael Fried Kuno Lehmann Rudolf W Ammann Stephan R Vavricka | 2014 | World Journal of Gastroenterology2014，20，19： | 5 |
| 2 | Mucosal healing and deep remission: What does it mean?显示文摘The use of specific terms under different meanings and varying definitions has always been a source of confusion in science.When we point our efforts towards an evidence based medicine for inflammatory bowel diseases(IBD)the same is true:Terms such as'mucosal healing'or'deep remission'as endpoints in clinical trials or treatment goals in daily patient care may contribute to misconceptions if meanings change over time or definitions are altered.It appears to be useful to first have a look at the development of terms and their definitions,to assess their intrinsic and context-independent problems and then to analyze the different relevance in present-day clinical studies and trials.The purpose of such an attempt would be to gain clearer insights into the true impact of the clinical findings behind the terms.It may also lead to a better defined use of those terms for future studies.The terms'mucosal healing'and'deep remission'have been introduced in recent years as new therapeutic targets in the treatment of IBD patients.Several clinical trials,cohort studies or inception cohorts provided data that the long term disease course is better,when mucosal healing is achieved.However,it is still unclear whether continued or increased therapeutic measures will aid or improve mucosal healing for patients in clinical remission.Clinical trials are under way to answer this question.Attention should be paid to clearly address what levels of IBD activity are looked at.In the present review article authors aim to summarize the current evidence available on mucosal healing and deep remission and try to highlight their value and position in the everyday decision making for gastroenterologists. | Gerhard Rogler Stephan Vavricka Alain Schoepfer Peter L Lakatos | 2013 | World Journal of Gastroenterology2013，19，43： | 4 |
| 3 | Endoscopy for repeatedly ingested sharp foreign bodies in patients with borderline personality disorder: an international survey显示文摘 | Cornelia M. Frei-Lanter Stephan R. Vavricka Tillmann H.C. Kruger Radu Tutuian Andreas Geier Peter Bauerfeind Tanja Krones Michael Fried Pascal Frei | 2012 | European Journal of Gastroenterology & Hepatology2012，，7： | 1 |
| 4 | Tumor necrosis factor-α and interferon-γ increase PepT1 expression and activity in the human colon carcinoma cell line Caco-2/bbe and in mouse intestine显示文摘 | Stephan R. Vavricka Mark W. Musch Mikihiro Fujiya Keri Kles Laura Chang Jyrki J. Eloranta Gerd A. Kullak-Ublick Ken Drabik Didier Merlin Eugene B. Chang | 2006 | Pflügers Archiv - European Journal of Physiology2006，，1： | 1 |
| 5 | Extraintestinal Manifestations of Inflammatory Bowel Disease显示文摘 | Stephan R. Vavricka Alain Schoepfer Michael Scharl Peter L. Lakatos Alexander Navarini Gerhard Rogler | 2015 | Inflammatory Bowel Diseases2015，，8： | 1 |
| 6 | Periodontitis and Gingivitis in Inflammatory Bowel Disease: A Case–Control Study显示文摘 | Stephan R. Vavricka Christine N. Manser Sebastian Hediger Marius V?gelin Michael Scharl Luc Biedermann Sebastian Rogler Frank Seibold René Sanderink Thomas Attin Alain Schoepfer Michael Fried Gerhard Rogler Pascal Frei | 2013 | Inflammatory Bowel Diseases2013，，13： | 1 |
| 7 | Tumor necrosis factor-α and interferon-γ increase PepT1expression and activity in the human colon carcinoma cell line Caco-2/bbe and in mouse intestine显示文摘 | Stephan R Vavricka Mark W Musch Mikihiro Fujiya | 2006 | Pflugers Arch Eur J Physiol2006，452，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员